Financial Review: Immune Pharmaceuticals (IMNP) and Theravance Biopharma (TBPH)

Immune Pharmaceuticals (NASDAQ: IMNP) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Profitability

This table compares Immune Pharmaceuticals and Theravance Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Immune Pharmaceuticals N/A -1,443.76% -117.17%
Theravance Biopharma -1,604.87% -99.43% -47.10%

Institutional & Insider Ownership

1.6% of Immune Pharmaceuticals shares are held by institutional investors. Comparatively, 86.0% of Theravance Biopharma shares are held by institutional investors. 6.7% of Immune Pharmaceuticals shares are held by company insiders. Comparatively, 6.1% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Immune Pharmaceuticals has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 2.35, meaning that its share price is 135% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Immune Pharmaceuticals and Theravance Biopharma, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immune Pharmaceuticals 0 0 1 0 3.00
Theravance Biopharma 1 0 5 0 2.67

Immune Pharmaceuticals currently has a consensus price target of $3.00, suggesting a potential upside of 400.00%. Theravance Biopharma has a consensus price target of $42.67, suggesting a potential upside of 47.43%. Given Immune Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Immune Pharmaceuticals is more favorable than Theravance Biopharma.

Valuation & Earnings

This table compares Immune Pharmaceuticals and Theravance Biopharma’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immune Pharmaceuticals N/A N/A -$32.66 million ($3.00) -0.20
Theravance Biopharma $48.65 million 32.18 -$190.66 million ($5.16) -5.61

Immune Pharmaceuticals has higher earnings, but lower revenue than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than Immune Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Immune Pharmaceuticals beats Theravance Biopharma on 8 of the 13 factors compared between the two stocks.

Immune Pharmaceuticals Company Profile

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply